Home > Neurology > Novel neuroimaging data have implications for recruitment for Alzheimer’s clinical trials

Novel neuroimaging data have implications for recruitment for Alzheimer’s clinical trials


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Neurology
Reuters Health - 21/10/2020 - There is a quantitative association between initial beta-amyloid levels on positron emission tomography (PET) and subsequent tau accumulation on PET in older cognitively normal adults, report researchers with the Alzheimer's Disease Neuroimaging Initiative (ADNI). This new observation could be important when recruiting cognitively normal older adults to clinical trials where tau accumulation is an outcome measure, they write in JAMA Neurology. Tau accumulation seen on PET imaging is closely tied to cognitive problems and is a potential surrogate outcome measure for clinical trial of Alzheimer's disease, Dr. David Knopman of Mayo Clinic, in Rochester, Minnesota, and colleagues explain. It's generally thought that elevated levels of beta-amyloid on PET are associated with elevated tau and tau accumulation. But whether the risk for tau accumulation is uniform in all older adults considered amyloid-positive or whether risk increases ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on